Metformin for diabetes prevention: update of the evidence base

References

• Feng X, Astell-Burt T. Impact of a type 2 diabetes diagnosis on mental health, quality of life, and social contacts: a longitudinal study. BMJ Open Diabetes Res Care. 2017;5(1):e000198.
   PubMed Web of Science ®Google Scholar
• Cai X, Zhang Y, Li M, et al. Association between prediabetes and risk of all cause mortality and cardiovascular disease: updated meta-analysis. BMJ. 2020;370:m2297.
   PubMed Web of Science ®Google Scholar
• Brannick B, Dagogo-Jack S. Prediabetes and cardiovascular disease: pathophysiology and interventions for prevention and risk reduction. Endocrinol Metab Clin North Am. 2018;47(1):33–50.
   PubMed Web of Science ®Google Scholar
• Merck Healthcare KGaA, Darmstadt, Germany, data on file.
   Google Scholar
• American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S15–S33.
   PubMed Web of Science ®Google Scholar
• Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255–323.
   PubMed Web of Science ®Google Scholar
• World Health Organization, International Diabetes Federation. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia. Report of a WHO/IDF consultation. Available at: https://www.who.int/diabetes/publications/Definition. and diagnosis of diabetes_new.pdf (accessed May 2021).
   Google Scholar
• Hostalek U, Gwilt M, Hildemann S. Therapeutic use of metformin in prediabetes and diabetes prevention. Drugs. 2015;75(10):1071–1094.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 3. Prevention or delay of type 2 diabetes: standards of medical care in diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S34–S39.
   PubMed Web of Science ®Google Scholar
• Yudkin JS. “Prediabetes”: are there problems with this label? Yes, the label creates further problems! Diabetes Care. 2016;39(8):1468–1471.
   PubMed Web of Science ®Google Scholar
• Li CL, Pan CY, Lu JM, et al. Effect of metformin on patients with impaired glucose tolerance. Diabet Med. 1999;16(6):477–481.
   PubMed Web of Science ®Google Scholar
• Wenying Y, Lixiang L, Jinwu Q, et al. The preventive effect of acarbose and metformin on the IGT population from becoming diabetes mellitus: a 3-year multicentral prospective study. Chin J Endocrinol Metab. 2001;17:131–134.
   Google Scholar
• Holman RR, Blackwell L, Stratton IM, et al. Six-year results from the early diabetes intervention trial. Diabet Med. 2003;20(Suppl 2):15.
   Google Scholar
• Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403.
   PubMed Web of Science ®Google Scholar
• Diabetes Prevention Program Research Group. Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program. Diabetes Care. 2003;26:977–980.
   PubMed Web of Science ®Google Scholar
• O'Brien MJ, Whitaker RC, Yu D, et al. The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Prev Med. 2015;77:125–130.
   PubMed Web of Science ®Google Scholar
• Herman WH, Pan Q, Edelstein SL, et al. Impact of lifestyle and metformin interventions on the risk of progression to diabetes and regression to normal glucose regulation in overweight or obese people with impaired glucose regulation. Diabetes Care. 2017;40(12):1668–1677.
   PubMed Web of Science ®Google Scholar
• Ratner R, Goldberg R, Haffner S, et al. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. Diabetes Care. 2005;28:888–894.
   PubMed Web of Science ®Google Scholar
• Orchard TJ, Temprosa M, Goldberg R, et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med. 2005;142(8):611–619.
   PubMed Web of Science ®Google Scholar
• Goldberg R, Temprosa M, Otvos J, et al. Lifestyle and metformin treatment favorably influence lipoprotein subfraction distribution in the Diabetes Prevention Program. J Clin Endocrinol Metab. 2013;98(10):3989–3998.
   PubMed Web of Science ®Google Scholar
• Goldberg RB, Temprosa M, Haffner S, et al. Effect of progression from impaired glucose tolerance to diabetes on cardiovascular risk factors and its amelioration by lifestyle and metformin intervention: the Diabetes Prevention Program randomized trial by the Diabetes Prevention Program Research Group. Diabetes Care. 2009;32(4):726–732.
   PubMed Web of Science ®Google Scholar
• Krakoff J, Clark JM, Crandall JP, et al. Effects of metformin and weight loss on serum alanine aminotransferase activity in the diabetes prevention program. Obesity. 2010;18(9):1762–1767.
   PubMed Web of Science ®Google Scholar
• Haffner S, Temprosa M, Crandall J, et al. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes. 2005;54:1566–1572.
   PubMed Web of Science ®Google Scholar
• Goldberg RB, Temprosa MG, Mather KJ, et al. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care. 2014;37(8):2253–2260.
   PubMed Web of Science ®Google Scholar
• Diabetes Prevention Program Research Group. Changes in albumin excretion in the diabetes prevention program. Diabetes Care. 2009;32:720–725.
   PubMed Web of Science ®Google Scholar
• Friedman AN, Marrero D, Ma Y, et al. Value of urinary albumin-to-creatinine ratio as a predictor of type 2 diabetes in pre-diabetic individuals. Diabetes Care. 2008;31(12):2344–2348.
   PubMed Web of Science ®Google Scholar
• Kim C, Edelstein SL, Crandall JP, et al. Menopause and risk of diabetes in the Diabetes Prevention Program. Menopause. 2011;18(8):857–868.
   PubMed Web of Science ®Google Scholar
• Florez H, Pan Q, Ackermann RT, et al. Impact of lifestyle intervention and metformin on health-related quality of life: the diabetes prevention program randomized trial. J Gen Intern Med. 2012;27(12):1594–1601.
   PubMed Web of Science ®Google Scholar
• Jablonski KA, McAteer JB, de Bakker PI, et al. Common variants in 40 genes assessed for diabetes incidence and response to metformin and lifestyle intervention in the diabetes prevention program. Diabetes. 2010;59(10):2672–2681.
   PubMed Web of Science ®Google Scholar
• Hivert MF, Christophi CA, Franks PW, et al. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in diabetes prevention program participants. Diabetes. 2016;65(2):520–526.
   PubMed Web of Science ®Google Scholar
• Diabetes Prevention Program Research Group. Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care. 2003;26:2518–2523.
   PubMed Web of Science ®Google Scholar
• Herman WH, Hoerger TJ, Brandle M, et al. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med. 2005;142(5):323–332.
   PubMed Web of Science ®Google Scholar
• Ramachandran A, Snehalatha C, Mary S, et al. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia. 2006;49(2):289–297.
   PubMed Web of Science ®Google Scholar
• Zinman B, Harris SB, Neuman J, et al. Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. Lancet. 2010;376(9735):103–111.
   PubMed Web of Science ®Google Scholar
• Iqbal Hydrie MZ, Basit A, Shera AS, Hussain A. Effect of intervention in subjects with high risk of diabetes mellitus in Pakistan. J Nutr Metab. 2012;2012:867604.
   PubMedGoogle Scholar
• Hostalek U, Zilahi Z. Observational study of the efficacy of prolonged-release metformin in people with prediabetes. Curr Med Res Opin. 2020;36(3):397–401.
   PubMed Web of Science ®Google Scholar
• Lehtovirta M, Forsén B, Gullström M, et al. Metabolic effects of metformin in patients with impaired glucose tolerance. Diabet Med. 2001;18(7):578–583.
   PubMed Web of Science ®Google Scholar
• Florez H, Temprosa MG, Orchard TJ, et al. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes Obes Metab. 2014;16(4):326–333.
   PubMed Web of Science ®Google Scholar
• Zhang C, Gao F, Luo H, et al. Differential response in levels of high-density lipoprotein cholesterol to one-year metformin treatment in prediabetic patients by race/ethnicity. Cardiovasc Diabetol. 2015;14:79.
   PubMed Web of Science ®Google Scholar
• Malin SK, Nightingale J, Choi SE, et al. Metformin modifies the exercise training effects on risk factors for cardiovascular disease in impaired glucose tolerant adults. Obesity. 2013;21(1):93–100.
   PubMed Web of Science ®Google Scholar
• Brown JS, Wing R, Barrett-Connor E, et al. Lifestyle intervention is associated with lower prevalence of urinary incontinence: the Diabetes Prevention Program. Diabetes Care. 2006;29(2):385–390.
   PubMed Web of Science ®Google Scholar
• Hivert MF, Jablonski KA, Perreault L, et al. Updated genetic score based on 34 confirmed type 2 diabetes Loci is associated with diabetes incidence and regression to normoglycemia in the diabetes prevention program. Diabetes. 2011;60(4):1340–1348.
   PubMed Web of Science ®Google Scholar
• Florez JC, Jablonski KA, Bayley N, et al. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med. 2006;355(3):241–250.
   PubMed Web of Science ®Google Scholar
• Florez JC, Jablonski KA, McAteer JB, et al. Effects of genetic variants previously associated with fasting glucose and insulin in the Diabetes Prevention Program. PLOS One. 2012;7(9):e44424.
   PubMed Web of Science ®Google Scholar
• Florez JC, Jablonski KA, Taylor A, et al. The C allele of ATM rs11212617 does not associate with metformin response in the Diabetes Prevention Program. Diabetes Care. 2012;35(9):1864–1867.
   PubMed Web of Science ®Google Scholar
• Delahanty LM, Pan Q, Jablonski KA, et al. Genetic predictors of weight loss and weight regain after intensive lifestyle modification, metformin treatment, or standard care in the Diabetes Prevention Program. Diabetes Care. 2012;35(2):363–366.
   PubMed Web of Science ®Google Scholar
• Guardado-Mendoza R, Salazar-López SS, Álvarez-Canales M, et al. The combination of linagliptin, metformin and lifestyle modification to prevent type 2 diabetes (PRELLIM). A randomized clinical trial. Metabolism. 2020;104:154054.
   PubMed Web of Science ®Google Scholar
• O’Brien MJ, Perez A, Scanlan AB, et al. PREVENT-DM comparative effectiveness trial of lifestyle intervention and metformin. Am J Prev Med. 2017;52(6):788–797.
   PubMed Web of Science ®Google Scholar
• Ji L, Sun N, Zhang Y, et al. Efficacy of metformin in preventing progression to diabetes in a Chinese population with impaired glucose regulation: Protocol for a multicentre, open-label, randomized controlled clinical study. Diabetes Obes Metab. 2020;22(2):158–166.
   PubMed Web of Science ®Google Scholar
• Alnasrallah B, Pilmore H, Manley P. Protocol for a pilot randomised controlled trial of metformin in pre-diabetes after kidney transplantation: the Transplantation and Diabetes (Transdiab) study. BMJ Open. 2017;7(8):e016813.
   PubMed Web of Science ®Google Scholar
• Alnasrallah B, Goh TL, Chan LW, et al. Transplantation and diabetes (Transdiab): a pilot randomised controlled trial of metformin in impaired glucose tolerance after kidney transplantation. BMC Nephrol. 2019;20(1):147.
   PubMed Web of Science ®Google Scholar
• Rodríguez LA, Barquera S, Aguilar-Salinas CA, et al. Design of a cluster-randomized trial of the effectiveness and cost-effectiveness of metformin on prevention of type 2 diabetes among prediabetic Mexican adults (the PRuDENTE initiative of Mexico City). Contemp Clin Trials. 2020;95:106067.
   PubMed Web of Science ®Google Scholar
• Griffin SJ, Bethel MA, Holman RR, et al. Metformin in non-diabetic hyperglycaemia: the GLINT feasibility RCT. Health Technol Assess. 2018;22(18):1–64.
   Web of Science ®Google Scholar
• Htet TD, Godneva A, Liu Z, et al. Rationale and design of a randomised controlled trial testing the effect of personalised diet in individuals with pre-diabetes or type 2 diabetes mellitus treated with metformin. BMJ Open. 2020;10:e037859.
   PubMed Web of Science ®Google Scholar
• Dunlay SM, Givertz MM, Aguilar D, et al. Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America: this statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. Circulation. 2019;140(7):e294–e324.
   PubMed Web of Science ®Google Scholar
• Wiggers H, Køber L, Gislason G, et al. The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART): a 2 × 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with chronic heart failure and diabetes or prediabetes (Met-HeFT). Am Heart J. 2021;231:137–146.
   PubMed Web of Science ®Google Scholar
• Petrie JR, Rossing PR, Campbell IW. Metformin and cardiorenal outcomes in diabetes: a reappraisal. Diabetes Obes Metab. 2020;22(6):904–915.
   PubMed Web of Science ®Google Scholar
• Barzilay JI, Blaum C, Moore T, et al. Insulin resistance and inflammation as precursors of frailty: the Cardiovascular Health Study. Arch Intern Med. 2007;167(7):635–641.
   PubMedGoogle Scholar
• García-Esquinas E, Graciani A, Guallar-Castillón P, et al. Diabetes and risk of frailty and its potential mechanisms: a prospective cohort study of older adults. J Am Med Dir Assoc. 2015;16(9):748–754.
   PubMed Web of Science ®Google Scholar
• Yoon SJ, Kim KI. Frailty and disability in diabetes. Ann Geriatr Med Res. 2019;23(4):165–169.
   PubMed Web of Science ®Google Scholar
• National Institute of Diabetes and Digestive and Kidney Diseases. Diabetes Prevention Program Outcomes Study (DPPOS). Available at: https://repository.niddk.nih.gov/studies/dppos (accessed May 2021).
   Google Scholar
• Diabetes Prevention Program Research Group. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;374:1677–1686.
   PubMed Web of Science ®Google Scholar
• Diabetes Prevention Program Research Group. The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS. Diabetes Care. 2012;35:723–730.
   PubMed Web of Science ®Google Scholar
• Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcome Study (DPPOS). Diabetes. 2015;64:989–998.
   PubMed Web of Science ®Google Scholar
• Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol. 2015;3:866–875.
   PubMed Web of Science ®Google Scholar
• Diabetes Prevention Program Group and Diabetes Prevention Program Outcome Study Research Group. New data on clinical outcomes from the Diabetes Prevention Program Outcomes Study. Presentation at the 80th Virtual Scientific Sessions of the American Diabetes Association. 2020.
   Google Scholar
• American Diabetes Association. New data from Diabetes Prevention Program Outcomes Study shows persistent reduction of type 2 diabetes development over 22-year average follow-up. 2020. Available at: https://www.diabetes.org/newsroom/press-releases/2020/new-data-from-diabetes-prevention-program-outcomes-study-shows-persistent-reduction-of-t2d-development-over-22-year-average-follow-up (accessed May 2021).
   Google Scholar
• Busko M. DPPOS at 22 years: ‘diabetes prevention is possible’ long term. Medscape Diabetes & Endocrinology. Available at: https://www.medscape.com/viewarticle/932876 (accessed May 2021).
   Google Scholar
• Gong Q, Zhang P, Wang J, et al. Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the Da Qing Diabetes Prevention Outcome Study. Lancet Diabetes Endocrinol. 2019;7(6):452–461.
   PubMed Web of Science ®Google Scholar
• Diabetes Prevention Program Research Group. Long-term effects of metformin on diabetes prevention: identification of subgroups that benefited most in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study. Diabetes Care. 2019;42:601–608.
   PubMed Web of Science ®Google Scholar
• Diabetes Prevention Program Research Group. Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care. 2012;35:731–737.
   PubMed Web of Science ®Google Scholar
• Nasir K, Cainzos-Achirica M. Role of coronary artery calcium score in the primary prevention of cardiovascular disease. BMJ. 2021;373:n776.
   PubMed Web of Science ®Google Scholar
• Goldberg RB, Aroda VR, Bluemke DA, et al. Effect of long-term metformin and lifestyle in the diabetes prevention program and its outcome study on coronary artery calcium. Circulation. 2017;136(1):52–64.
   PubMed Web of Science ®Google Scholar
• Sardu C, Paolisso P, Sacra C, et al. Effects of metformin therapy on coronary endothelial dysfunction in patients with prediabetes with stable angina and nonobstructive coronary artery stenosis: The CODYCE Multicenter Prospective Study. Diabetes Care. 2019;42(10):1946–1955.
   PubMed Web of Science ®Google Scholar
• Luchsinger JA, Ma Y, Christophi CA, et al. Metformin, lifestyle intervention, and cognition in the Diabetes Prevention Program Outcomes Study. Dia Care. 2017;40(7):958–965.
   PubMed Web of Science ®Google Scholar
• Andreadis EA, Katsanou PM, Georgiopoulos DX, et al. The effect of metformin on the incidence of type 2 diabetes mellitus and cardiovascular disease risk factors in overweight and obese subjects–the Carmos study. Exp Clin Endocrinol Diabetes. 2009;117(4):175–180.
   PubMed Web of Science ®Google Scholar
• Barua M, Pathan F, Nabi MU, et al. Assessment of clinical and biochemical profile of prediabetic subject in Bangladesh, attending in BIRDEM and results of intervention by lifestyle modification, metformin, and DPP4 inhibitor. Diabetes Metab Syndr. 2019;13(2):1603–1608.
   PubMed Web of Science ®Google Scholar
• Bellamy L, Casas JP, Hingorani AD, et al. Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. Lancet. 2009;373(9677):1773–1779.
   PubMed Web of Science ®Google Scholar
• Aroda VR, Christophi CA, Edelstein SL, Diabetes Prevention Program Research Group, et al. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10-year follow-up. J Clin Endocrinol Metab. 2015;100(4):1646–1653.
   PubMed Web of Science ®Google Scholar
• Ratner RE, Christophi CA, Metzger BE, et al. Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions. J Clin Endocrinol Metab. 2008;93(12):4774–4779.
   PubMed Web of Science ®Google Scholar
• Amaefule CE, Bolou A, Drymoussi Z, et al. Effectiveness and acceptability of metformin in preventing the onset of type 2 diabetes after gestational diabetes in postnatal women: a protocol for a randomised, placebo-controlled, double-blind feasibility trial—optimising health outcomes with Metformin to prevent diAbetes After pregnancy (OMAhA). BMJ Open. 2020;10(5):e036198.
   PubMed Web of Science ®Google Scholar
• Dennett CC, Simon J. The role of polycystic ovary syndrome in reproductive and metabolic health: overview and approaches for treatment. Diabetes Spectr. 2015;28(2):116–120.
   PubMedGoogle Scholar
• Guan Y, Wang D, Bu H, et al. The effect of metformin on polycystic ovary syndrome in overweight women: a systematic review and meta-analysis of randomized controlled trials. Int J Endocrinol. 2020;2020:1–12. 5150684.
   Web of Science ®Google Scholar
• Practice Committee of the American Society for Reproductive Medicine. Role of metformin for ovulation induction in infertile patients with polycystic ovary syndrome (PCOS): a guideline. Fertil Steril. 2017;108:426–441.
   PubMed Web of Science ®Google Scholar
• Zhu T, Cui J, Goodarzi MO. Polycystic ovary syndrome and risk of type 2 diabetes, coronary heart disease, and stroke. Diabetes. 2021;70(2):627–637.
   PubMed Web of Science ®Google Scholar
• Doi SAR, Furuya-Kanamori L, Toft E, et al. Metformin in pregnancy to avert gestational diabetes in women at high risk: Meta-analysis of randomized controlled trials. Obes Rev. 2020;21(1):e12964.
   PubMed Web of Science ®Google Scholar
• Bidhendi Yarandi R, Behboudi-Gandevani S, Amiri M, et al. Metformin therapy before conception versus throughout the pregnancy and risk of gestational diabetes mellitus in women with polycystic ovary syndrome: a systemic review, meta-analysis and meta-regression. Diabetol Metab Syndr. 2019;11:58.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Group and individual-level interventions to prevent type 2 diabetes among people at high risk. Available at https://pathways.nice.org.uk/pathways/preventing-type-2-diabetes#path=view%3A/pathways/preventing-type-2-diabetes/group-and-individual-level-interventions-to-prevent-type-2-diabetes-among-people-at-high-risk.xml (accessed May 2021).
   Google Scholar
• Liu C, Foti K, Grams ME, et al. Trends in self-reported prediabetes and metformin use in the USA: NHANES 2005-2014. J Gen Intern Med. 2020;35(1):95–101.
   PubMed Web of Science ®Google Scholar
• Tseng E, Yeh HC, Maruthur NM. Metformin use in prediabetes among U.S. adults, 2005–2012. Diabetes Care. 2017;40(7):887–893.
   PubMed Web of Science ®Google Scholar
• Stirling DL, Onor I, Sarpong D, et al. Prescribing patterns of metformin in high-risk patients with prediabetes. J LA State Med Soc. 2015;167(6):257–262.
   PubMedGoogle Scholar
• Moin T, Martin JM, Mangione CM, et al. Choice of intensive lifestyle change and/or metformin after shared decision making for diabetes prevention: results from the prediabetes informed decisions and education (PRIDE) study. Med Decis Making. 2021;41(5):607–613.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Abdul-Ghani MA. Preservation of β-cell function: the key to diabetes prevention. J Clin Endocrinol Metab. 2011;96(8):2354–2366.
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854–865.
   PubMed Web of Science ®Google Scholar
• Horsburgh S, Sharples K, Barson D, et al. Patterns of metformin monotherapy discontinuation and reinitiation in people with type 2 diabetes mellitus in New Zealand. PLOS One. 2021;16(4):e0250289.
   PubMed Web of Science ®Google Scholar
• Walker EA, Gonzalez JS, Tripputi MT, et al. Long-term metformin adherence in the Diabetes Prevention Program Outcomes Study. BMJ Open Diab Res Care. 2020;8(1):e001537.
   PubMed Web of Science ®Google Scholar
• Christofides EA. Practical insights into improving adherence to metformin therapy in patients with type 2 diabetes. Clin Diabetes. 2019;37(3):234–241.
   PubMedGoogle Scholar
• Donnelly LA, Morris AD, Pearson ER. Adherence in patients transferred from immediate release metformin to a sustained release formulation: a population-based study. Diabetes Obes Metab. 2009;11(4):338–342.
   PubMed Web of Science ®Google Scholar
• Howlett HC, Bailey CJ. A risk-benefit assessment of metformin in type 2 diabetes mellitus. Drug Saf. 1999;20(6):489–503.
   PubMed Web of Science ®Google Scholar
• Feher MD, Al-Mrayat M, Brake J, et al. Tolerability of prolonged-release metformin (Glucophage® SR) in individuals intolerant to standard metformin — results from four UK centres. Diabetes Vasc Dis. 2007;7(5):225–228.
   Google Scholar
• Alvarez M, Sierra OR, Saavedra G, et al. Vitamin B12 deficiency and diabetic neuropathy in patients taking metformin: a cross-sectional study. Endocr Connect. 2019;8(10):1324–1329.
   PubMed Web of Science ®Google Scholar
• Aroda VR, Edelstein SL, Goldberg RB, et al. Long-term metformin use and vitamin B12 deficiency in the diabetes prevention program outcomes study. J Clin Endocrinol Metab. 2016;101(4):1754–1761.
   PubMed Web of Science ®Google Scholar
• Campbell IW, Howlett HCS, Holman RR, et al. (Eds). Metformin: 60 years of clinical experience. In Addendum to the scientific handbook. Weinheim: WILEY-VCH Verlag GmbH & Co. KGaA; 2016.
   Google Scholar
• Roberts S, Barry E, Craig D, et al. Preventing type 2 diabetes: systematic review of studies of cost-effectiveness of lifestyle programmes and metformin, with and without screening, for pre-diabetes. BMJ Open. 2017;7(11):e017184.
   PubMed Web of Science ®Google Scholar
• Schmidt SK, Hemmestad L, MacDonald CS, et al. Motivation and barriers to maintaining lifestyle changes in patients with type 2 diabetes after an intensive lifestyle intervention (the U-TURN trial): a longitudinal qualitative study. IJERPH. 2020;17(20):7454.
   Web of Science ®Google Scholar
• Sampson M, Clark A, Bachmann M, et al. Lifestyle intervention with or without lay volunteers to prevent type 2 diabetes in people with impaired fasting glucose and/or nondiabetic hyperglycemia: a randomized clinical. JAMA Intern Med. 2021;181(2):168–178.
   PubMed Web of Science ®Google Scholar
• Roberts S, Craig D, Adler A, et al. Economic evaluation of type 2 diabetes prevention programmes: Markov model of low- and high-intensity lifestyle programmes and metformin in participants with different categories of intermediate hyperglycaemia. BMC Med. 2018;16(1):16.
   PubMed Web of Science ®Google Scholar
• Png ME, Yoong JS. Evaluating the cost-effectiveness of lifestyle modification versus metformin therapy for the prevention of diabetes in Singapore. PLOS One. 2014;9(9):e107225.
   PubMed Web of Science ®Google Scholar
• Maayan L, Vakhrusheva J, Correll CU. Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis. Neuropsychopharmacology. 2010;35(7):1520–1530.
   PubMed Web of Science ®Google Scholar
• Warrilow A, Somerset S, Pumpa K, et al. Metformin use in prediabetes: is earlier intervention better? Acta Diabetol. 2020;57(11):1359–1366.
   PubMed Web of Science ®Google Scholar
• Apolzan JW, Venditti EM, Edelstein SL, et al. Long-term weight loss with metformin or lifestyle intervention in the Diabetes Prevention Program Outcomes Study. Ann Intern Med. 2019;170(10):682–690.
   PubMed Web of Science ®Google Scholar
• Hazuda HP, Pan Q, Florez H, et al. Association of intensive lifestyle and metformin interventions with frailty in the Diabetes Prevention Program Outcomes Study. J Gerontol A Biol Sci Med Sci. 2021;76(5):929–936.
   PubMed Web of Science ®Google Scholar
• Heckman-Stoddard BM. New Data on Clinical Outcomes from the Diabetes Prevention Program Outcomes Study (DPPOS). Presentation at the 80th Scientific Sessions of the American Diabetes Association, June 12–16, 2020.
   Google Scholar